Oncopeptides AB (publ) (STO:ONCO)
Sweden · Delayed Price · Currency is SEK 1.780
-0.109 (-5.77%)
Sep 4, 2026, 5:29 PM CET
Oncopeptides AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 95.15 | 71.12 | 31.65 | 35.22 | 8.36 | 118.3 | |
Revenue Growth | 87.05% | 124.72% | -10.14% | 321.54% | -92.94% | - |
Cost of Revenue | 3.43 | 2.45 | 2.66 | -1.08 | 0.01 | 53.12 |
Gross Profit | 91.73 | 68.67 | 28.99 | 36.3 | 8.35 | 65.17 |
Selling, General & Admin | 195.93 | 194.62 | 197.28 | 188.48 | 142.2 | 873.81 |
Research & Development | 98.22 | 102.97 | 121.19 | 106.95 | 217.66 | 679.93 |
Other Operating Expenses | -6.66 | -3.29 | -6.9 | -6.34 | -4.57 | 3.9 |
Operating Expenses | 287.49 | 294.31 | 311.57 | 289.09 | 355.29 | 1,558 |
Operating Income | -195.77 | -225.64 | -282.59 | -252.79 | -346.94 | -1,492 |
Interest Expense | -7.56 | -14.45 | -12.66 | -5.79 | -0.88 | -0.95 |
Interest & Investment Income | 1.95 | 1.95 | 8.2 | 8.59 | 2.62 | 0.49 |
Currency Exchange Gain (Loss) | 3.01 | 3.01 | -1.82 | 1.54 | 8.96 | 71.54 |
Other Non Operating Income (Expenses) | -12.33 | -12.33 | 4.66 | - | - | 0 |
EBT Excluding Unusual Items | -210.7 | -247.46 | -284.21 | -248.45 | -336.24 | -1,421 |
Gain (Loss) on Sale of Investments | -0.71 | -0.71 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -1.44 | - |
Pretax Income | -211.41 | -248.17 | -284.21 | -248.45 | -337.68 | -1,421 |
Income Tax Expense | 1.55 | 1.42 | 0.4 | 0.66 | 0.27 | 8.95 |
Net Income | -212.96 | -249.59 | -284.61 | -249.11 | -337.95 | -1,430 |
Net Income to Common | -212.96 | -249.59 | -284.61 | -249.11 | -337.95 | -1,430 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 281 | 227 | 166 | 90 | 82 | 75 |
Shares Outstanding (Diluted) | 281 | 227 | 166 | 90 | 82 | 75 |
Shares Change | 32.63% | 36.37% | 84.14% | 9.80% | 9.33% | 20.72% |
EPS (Basic) | -0.76 | -1.10 | -1.71 | -2.76 | -4.11 | -19.00 |
EPS (Diluted) | -0.76 | -1.10 | -1.71 | -2.76 | -4.11 | -19.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -188.56 | -222.88 | -260.93 | -279.61 | -423.02 | -1,517 |
Free Cash Flow Per Share | -0.67 | -0.98 | -1.57 | -3.09 | -5.14 | -20.14 |
Gross Margin | 96.40% | 96.55% | 91.59% | 103.06% | 99.93% | 55.09% |
Operating Margin | -205.74% | -317.27% | -892.91% | -717.74% | -4152.44% | -1261.64% |
Profit Margin | -223.81% | -350.94% | -899.29% | -707.30% | -4044.90% | -1209.11% |
Free Cash Flow Margin | -198.17% | -313.40% | -824.47% | -793.89% | -5063.03% | -1282.16% |
EBITDA | -193.59 | -223.36 | -280.12 | -250.35 | -344.93 | -1,491 |
D&A For EBITDA | 2.18 | 2.28 | 2.47 | 2.44 | 2.01 | 1.72 |
EBIT | -195.77 | -225.64 | -282.59 | -252.79 | -346.94 | -1,492 |